

MD7009/MD7259 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies

View Online



1.

Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein. Textbook of Diabetes [Internet]. John Wiley; 2016. Available from: <https://ebookcentral-proquest-com.ezproxy4.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056>

2.

Type 2 diabetes in adults: management | Guidance and guidelines | NICE. Available from: <https://www.nice.org.uk/guidance/ng28>

3.

Resources and tools [Internet]. Available from: <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html>

4.

Resources and tools [Internet]. Available from: <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/79:global-guideline-for-type-2-diabetes.html>

5.

Resources and tools [Internet]. Available from: <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/80:the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html>

6.

Crasto W, Jarvis J, Davies MJ. Handbook of insulin therapies [Internet]. Switzerland: Adis; 2016. Available from:
http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

7.

Anthony H. Barnett, Jenny Grice. New Mechanisms in Glucose Control [Internet]. BMJ Books; 1 edition; 2013. Available from:
<http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133>

8.

WHO 2011 Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus [Internet]. Available from:
http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/

9.

Atkinson MA. The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine. 2012 Nov 1;2(11):a007641–a007641.

10.

Samuel VT, Shulman GI. Integrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell. 2012 Mar;148(5):852–71.

11.

Beverly M Shields. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open [Internet]. 2015;5(11). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636628/?report=classic>

12.

Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgraduate Medical Journal*. 2016 Feb;92(1084):63–9.

13.

Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabetic Medicine*. 2013 Jul;30(7):803–17.

14.

Srinivasan BT, Jarvis J, Khunti K, Davies MJ. Recent advances in the management of type 2 diabetes mellitus: a review. *Postgraduate Medical Journal*. 2008 Oct 1;84(996):524–31.

15.

Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. *PEDIATRICS*. 2013 Feb 1;131(2):364–82.

16.

Celia G. Walker. Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk. *PLoS ONE* [Internet]. 2015;10(7). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496090/>

17.

Chatterjee S, Davies M. Type 2 diabetes: recent advances in diagnosis and management. *Prescriber*. 2015 May 19;26(10):15–21.

18.

Ismail-Beigi F. Glycemic Management of Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 2012 Apr 5;366(14):1319–27.

19.

Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2006 Aug 1;29(8):1963–72.

20.

Srinivasan BT, Davies M. Glycaemic management of type 2 diabetes. *Medicine*. 2014 Dec;42(12):711–7.

21.

S M Attard. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. *Nutrition & Diabetes* [Internet]. 2015;5(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491857/>

22.

Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR, Aguilar RB. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β -Cell-Centric Classification Schema. *Diabetes Care*. 2016 Feb;39(2):179–86.

23.

Nolan CJ, Ruderman NB, Kahn SE, Pedersen O, Prentki M. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. *Diabetes*. 2015 Mar;64(3):673–86.

24.

Rizos CV, Kei A, Elisaf MS. The current role of thiazolidinediones in diabetes management. *Archives of Toxicology*. 2016 Aug;90(8):1861–81.

25.

Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. *New England Journal of Medicine*. 2007 Jun 14;356(24):2457–71.

26.

Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes [Internet]. 4AD. Available from: <https://www.youtube.com/watch?v=AhhWTmEFuag>

27.

[ARCHIVED CONTENT] Medicines management: Everybody's business : Department of Health - Publications and statistics [Internet]. Available from: http://webarchive.nationalarchives.gov.uk/20080205142458/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082200

28.

Vloemans AF, van Beers CAJ, de Wit M, Cleijne W, Rondags SM, Geelhoed-Duijvestijn PH, et al. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. *Diabetic Medicine*. 2017 Oct;34(10):1470-6.

29.

Sivasubramaniyam S, Amiel SA, Choudhary P. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. *Diabetic Medicine*. 2017 Oct;34(10):1456-60.

30.

Crasto W, Jarvis J, Davies MJ. Handbook of insulin therapies [Internet]. Switzerland: Adis; 2016. Available from: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

31.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2015 Jan;38(1):140-9.

32.

Ryder B, McKnight J, Blann A, Dhatariya K, Gregory R, Robinson T, et al. ABCD position statement on GLP-1 based therapies and pancreatic damage. *Practical Diabetes*. 2013 Nov;30(9):388-91.

33.

Garber AJ, King AB, Prato SD, Sreenan S, Balci MK, Muñoz-Torres M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *The Lancet*. 2012 Apr;379(9825):1498-507.

34.

Gururaj Setty S, Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal*. 2016 Mar;92(1085):152-64.

35.

Htike ZZ, Zaccardi F, Chatterjee S, Khunti K, Davies MJ. Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care. *British Journal of Diabetes*. 2016 Sep 18;16(3).

36.

Davies MJ, Chatterjee S. Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care. *Nature Reviews Endocrinology*. 2017 Apr 7;13(6):317-8.

37.

Gough SCL, Harris S, Woo V, Davies M. Insulin degludec: overview of a novel ultra long-acting basal insulin. *Diabetes, Obesity and Metabolism*. 2013 Apr;15(4):301-9.

38.

Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. *Diabetic Medicine*. 2006 Mar;23(3):285–92.

39.

Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. *The Lancet*. 2008 Mar;371(9618):1073–84.

40.

Funnell MM. Overcoming Barriers to the Initiation of Insulin Therapy. *Clinical Diabetes*. 2007 Jan 1;25(1):36–8.

41.

Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). *Diabetes, Obesity and Metabolism*. 2006 Jan;8(1):58–66.

42.

Gough SCL. A review of human and analogue insulin trials. *Diabetes Research and Clinical Practice*. 2007 Jul;77(1):1–15.

43.

Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? *Diabetes, Obesity and Metabolism*. 2007 Sep;9(5):630–9.

44.

Heller SR, Colagiuri S, Vaaler S, Wolffenbuttel BHR, Koelendorf K, Friberg HH, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects

with Type 1 diabetes. *Diabetic Medicine*. 2004 Jul;21(7):769-75.

45.

Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. *Diabetes Care*. 2006 Jun 1;29(6):1269-74.

46.

Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. *New England Journal of Medicine*. 2007 Oct 25;357(17):1716-30.

47.

Holman RR, Turner RC. A Practical Guide to Basal and Prandial Insulin Therapy. *Diabetic Medicine*. 1985 Jan;2(1):45-53.

48.

Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzner TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: *Cochrane Database of Systematic Reviews* [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: <http://doi.wiley.com/10.1002/14651858.CD005613.pub3>

49.

Marre M, Shaw J, Brändle M, Bebakar WMW, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabetic Medicine*. 2009 Mar;26(3):268-78.

50.

Young LA, Buse JB. GLP-1 receptor agonists and basal insulin in type 2 diabetes. *The Lancet*. 2014 Dec;384(9961):2180-1.

51.

Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*. 2010 Jun;375(9733):2234-43.

52.

Gururaj Setty S, Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal*. 2016 Mar;92(1085):152-64.

53.

Rosenstock J, Raccach D, Koranyi L, Maffei L, Boka G, Miossec P, et al. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). *Diabetes Care*. 2013 Oct 1;36(10):2945-51.

54.

Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. *Diabetes, Obesity and Metabolism*. 2011 Aug;13(8):677-84.

55.

Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. *Diabetes, Obesity and Metabolism*. 2012 Sep;14(9):780-8.

56.

Richter B, Neises G. 'Human' insulin versus animal insulin in people with diabetes mellitus. In: *Cochrane Database of Systematic Reviews* [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: <http://doi.wiley.com/10.1002/14651858.CD003816.pub2>

57.

Swinnen SG, Simon AC, Holleman F, Hoekstra JB, DeVries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: <http://doi.wiley.com/10.1002/14651858.CD006383.pub2>

58.

Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. *Diabetologia*. 2006 Mar;49(3):442–51.

59.

Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. *The Lancet*. 2011 Mar;377(9769):924–31.

60.

Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzner TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: <http://doi.wiley.com/10.1002/14651858.CD005613.pub3>

61.

Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. *Diabetologia*. 2008 Mar;51(3):408–16.

62.

Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, et al. Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. *Diabetes Care*. 2005 Feb 1;28(2):260–5.

63.

Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. *Diabetes Care*. 2005 Jun 1;28(6):1282-8.

64.

Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. *Diabetes, Obesity and Metabolism*. 2017 Apr;19(4):524-36.

65.

Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. *Diabetes, Obesity and Metabolism*. 2017 Apr;19(4):524-36.

66.

Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. *JAMA*. 2007 Jul 11;298(2).

67.

Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, et al. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. *Diabetes Care*. 2010 Jun 1;33(6):1255-61.

68.

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AYM, et al. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine*. 2011 Jan 18;154(2).

69.

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *The Lancet*. 2009 Jul;374(9683):39–47.

70.

Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. *The Lancet Diabetes & Endocrinology*. 2016 Jun;4(6):525–36.

71.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2016 Jul 28;375(4):311–22.

72.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2016 Nov 3;375(18):1797–9.

73.

Courtney H, Nayar R, Rajeswaran C, Jandhyala R. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2017 Mar;Volume 10:79–87.

74.

Rotz ME, Ganetsky VS, Sen S, Thomas TF. Implications of incretin-based therapies on cardiovascular disease. *International Journal of Clinical Practice*. 2015 May;69(5):531–49.

75.

Levin PA, Nguyen H, Wittbrodt E, Kim SC. Glucagon-like peptide-1 receptor agonists: a

systematic review of comparative effectiveness research. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2017 Apr;Volume 10:123–39.

76.

Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*. 2013 Sep 1;36(9):2489–96.

77.

Dungan KM, Povedano ST, Forst T, González JGG, Atisso C, Sealls W, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. *The Lancet*. 2014 Oct;384(9951):1349–57.

78.

Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). *Diabetes Care*. 2014 Aug;37(8):2149–58.

79.

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials- ClinicalKey [Internet]. Available from:
<https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858717301043?returnurl=null&referrer=null>

80.

Safety and insulin: Implementation of national guidance at a local level | Journal Content | Diabetesonthenet.com [Internet]. Available from:
<http://www.diabetesonthenet.com/journal-content/view/safety-and-insulin-implementation-of-national-guidance-at-a-local-level>

81.

Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C. Introduction of biosimilar insulins in Europe. *Diabetic Medicine*. 2017 Oct;34(10):1340–53.

82.

Crasto W, Jarvis J, Davies MJ. Handbook of insulin therapies [Internet]. Switzerland: Adis; 2016. Available from:
http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

83.

Standards of Medical Care in Diabetes--2015: Summary of Revisions. *Diabetes Care*. 2015 Jan 1;38(Supplement_1):S4–S4.

84.

Minimizing Hypoglycemia in Diabetes: Table 1. *Diabetes Care*. 2015 Aug;38(8):1583–91.

85.

Grammes J, Stock W, Mann CG, Flynn EM, Kubiak T. Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. *Diabetic Medicine*. 2017 Aug 30;

86.

Carver C. Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes. *The Diabetes Educator*. 2006 Nov;32(6):910–7.

87.

Mäkimmattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. *Diabetologia*. 1999 Mar 19;42(4):406–12.

88.

Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine*. 2017 Sep;34(9):1205–11.

89.

Simmons RK, Borch-Johnsen K, Lauritzen T, Rutten GE, Sandbæk A, van den Donk M, et al. A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. *Health Technology Assessment*. 2016 Aug;20(64):1–86.

90.

Kamlesh Khunti. Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. *PLoS ONE* [Internet]. 2015;10(9). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556656/?report=classic>

91.

Tao L, Wilson ECF, Wareham NJ, Sandbaek A, Rutten GEHM, Lauritzen T, et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. *Diabetic Medicine*. 2015 Jul;32(7):907–19.

92.

Gray LJ, Khunti K, Wilmot EG, Yates T, Davies MJ. External validation of two diabetes risk scores in a young UK South Asian population. *Diabetes Research and Clinical Practice*. 2014 Jun;104(3):451–8.

93.

Gray LJ, Khunti K, Edwardson C, Goldby S, Henson J, Morris DH, et al. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. *Diabetologia*. 2012 Dec;55(12):3238–44.

94.

Johnston BC, Kanters S, Bandayrel K, Wu P, Naji F, Siemieniuk RA, et al. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. *JAMA*. 2014 Sep 3;312(9).

95.

Steven S, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, et al. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. *Diabetes Care*. 2016 May;39(5):808-15.

96.

Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. *Diabetic Medicine*. 2015 Sep;32(9):1149-55.

97.

Persaud SJ, Jones PM. A Wake-up Call for Type 2 Diabetes? *New England Journal of Medicine*. 2016 Sep 15;375(11):1090-2.

98.

Dhatariya KK, Skedgel C, Fordham R. The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. *Diabetic Medicine*. 2017 Oct;34(10):1361-6.

99.

Crasto W, Jarvis J, Davies MJ. Handbook of insulin therapies [Internet]. Switzerland: Adis; 2016. Available from:
http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

100.

Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S, et al. Effectiveness of

the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ*. 2008 Mar 1;336(7642):491-5.

101.

Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *The Lancet*. 2012 Aug;380(9840):475-83.

102.

Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*. 2010 Jun;375(9733):2234-43.

103.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2016 Jul 28;375(4):311-22.

104.

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*. 2016 Jul 28;375(4):323-34.

105.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*. 2016 Nov 3;375(18):1799-802.

106.

Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, et al. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With

Sitagliptin (TECOS). *Diabetes Care*. 2017 Jan 5;

107.

Merlin C. Thomas. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. *Diabetes Therapy* [Internet]. 2016;7(3). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014795/>

108.

Paul Craddy. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. *Diabetes Therapy* [Internet]. 2014;5(1). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065303/>

109.

Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. *Annals of Internal Medicine*. 2011 May 3;154(9).

110.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2015 Jul 16;373(3):232-42.

111.

Min SH, Yoon JH, Hahn S, Cho YM. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. *Diabetes/Metabolism Research and Reviews*. 2017 Jan;33(1).

112.

Capehorn M, Polonsky WH, Edelman S, Belton A, Down S, Gamerman V, et al. Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia). *Diabetic Medicine*. 2017 Mar;

113.

Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. *Diabetes, Obesity and Metabolism*. 2016 Apr;18(4):333-47.

114.

Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*. 2015 Aug;109(2):378-88.

115.

Daly H, Davies M, Barnett J, Amin S, Gray G, Leonard J, et al. Development of a self-management education module for those with type 2 diabetes on injectable therapies. *Practical Diabetes*. 2015 Oct;32(8):305-310a.

116.

Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Diabetes, Obesity and Metabolism*. 2016 Mar;18(3):203-16.

117.

Frandsen CSS, Madsbad S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. *Diabetic Medicine*. 2014 Nov;31(11):1293-300.

118.

Hadjiconstantinou M, Byrne J, Bodicoat DH, Robertson N, Eborall H, Khunti K, et al. Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. *Journal of Medical Internet Research*. 2016 Oct 21;18(10).

119.

Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care* 2016;39:2126–2140. *Diabetes Care*. 2017 Feb;40(2):287.1-287.

120.

Tanner M. Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. *Annals of Internal Medicine*. 2016 Aug 16;165(4).

121.

Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*. 2015 Aug;109(2):378–88.

122.

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *The Lancet*. 2010 Jun;375(9733):2223–33.

123.

Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes, Obesity and Metabolism*. 2007 Mar;9(2):194–205.

124.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2016 Nov 10;375(19):1834–44.

125.

Anderson B, Funnell M, American Diabetes Association. The art of empowerment: stories and strategies for diabetes educators. 2nd ed. Alexandria, Va: American Diabetes Association; 2005.

126.

Crasto W, Jarvis J, Davies MJ. Handbook of insulin therapies [Internet]. Switzerland: Adis; 2016. Available from:
http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

127.

Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine*. 2012 Apr 26;366(17):1567–76.

128.

Leff DR, Heath D. Surgery for obesity in adulthood. *BMJ*. 2009 Sep 22;339(sep22 1):b3402–b3402.

129.

Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. *New England Journal of Medicine*. 2004 Dec 23;351(26):2683–93.

130.

Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*. 2017 Feb 16;376(7):641–51.

131.

Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine*. 2012 Apr 26;366(17):1567–76.

132.

Brown J, Alwan NA, West J, Brown S, McKinlay CJ, Farrar D, et al. Lifestyle interventions for the treatment of women with gestational diabetes. In: Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: <http://doi.wiley.com/10.1002/14651858.CD011970.pub2>

133.

Kenneth Hodson. Gestational diabetes: emerging concepts in pathophysiology. *Obstetric Medicine* [Internet]. 2010;3(4). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989628/?report=classic>

134.

Latika Sahu. Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. *Obstetric Medicine* [Internet]. 2009;2(4). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989660/?report=classic>

135.

Moreno-Castilla C, Mauricio D, Hernandez M. Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. *Current Diabetes Reports*. 2016 Apr;16(4).

136.

Postnatal testing following gestational diabetes- ClinicalKey [Internet]. Available from: <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858715003228?returnurl=null&referrer=null>

137.

Birkeland KI. Hyperglycaemia in pregnancy: still a lot to learn. *The Lancet Diabetes & Endocrinology*. 2015 Oct;3(10):752-3.

138.

Rinki Murphy. Monogenic diabetes and pregnancy. *Obstetric Medicine* [Internet]. 2015;8(3). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935018/>

139.

Stewart ZA, Wilinska ME, Hartnell S, Temple RC, Rayman G, Stanley KP, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. *New England Journal of Medicine*. 2016 Aug 18;375(7):644–54.

140.

Yeh JS, Kushner RF, Schiff GD. Obesity and Management of Weight Loss. *New England Journal of Medicine*. 2016 Sep 22;375(12):1187–9.

141.

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care [Internet]. Available from: <http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>

142.

Henson, Joseph. Associations of Sedentary Time with Fat Distribution in a High-Risk Population. 2014 Nov 10; Available from: <https://ira.le.ac.uk/handle/2381/32505>

143.

Crasto W, Jarvis J, Davies MJ. *Handbook of insulin therapies* [Internet]. Switzerland: Adis; 2016. Available from: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

144.

Srinivasan P, Huang GC, Amiel SA, Heaton ND. Islet cell transplantation. *Postgraduate Medical Journal*. 2007 Apr 1;83(978):224–9.

145.

Choudhary P, Parrott NR, Birtles L, Rutter MK. Islet cell transplantation: current status in the UK (2012). *Practical Diabetes*. 2012 Sep;29(7):280-5.

146.

Amy Kennedy. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. *PLoS ONE* [Internet]. 2013;8(3). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598953/>

147.

Chimen M, Kennedy A, Nirantharakumar K, Pang TT, Andrews R, Narendran P. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. *Diabetologia*. 2012 Mar;55(3):542-51.

148.

Umpierre D. Physical Activity Advice Only or Structured Exercise Training and Association With HbA_{1c} Levels in Type 2 Diabetes. *JAMA*. 2011 May 4;305(17).

149.

Avery L, Flynn D, van Wersch A, Sniehotta FF, Trenell MI. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. *Diabetes Care*. 2012 Dec 1;35(12):2681-9.

150.

Barry VW, Baruth M, Beets MW, Durstine JL, Liu J, Blair SN. Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. *Progress in Cardiovascular Diseases*. 2014 Jan;56(4):382-90.

151.

Qin L, Knol MJ, Corpeleijn E, Stolk RP. Does physical activity modify the risk of obesity for

type 2 diabetes: a review of epidemiological data. *European Journal of Epidemiology*. 2010 Jan;25(1):5-12.

152.

Lee IM. Physical Activity and Weight Gain Prevention. *JAMA*. 2010 Mar 24;303(12).

153.

John M Jakicic. Physical activity considerations for the treatment and prevention of obesity. *The American Journal of Clinical Nutrition* [Internet]. 2005 Jan 7;82(1):226S-229S. Available from: <http://ajcn.nutrition.org/content/82/1/226S>

154.

Heinonen I, Helajärvi H, Pahkala K, Heinonen OJ, Hirvensalo M, Pälve K, et al. Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. *BMJ Open*. 2013 May;3(6).

155.

Sallis JF, Bull F, Guthold R, Heath GW, Inoue S, Kelly P, et al. Progress in physical activity over the Olympic quadrennium. *The Lancet*. 2016 Sep;388(10051):1325-36.

156.

Hartman YAW, Jansen HJ, Hopman MTE, Tack CJ, Thijssen DHJ. Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. *Diabetes Care*. 2017 Sep;40(9):e120-1.

157.

Michael Riddell. Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. *Journal of diabetes science and technology* (Online) [Internet]. 2009;3(4). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/>